Targeting cancer with small-molecule pan-KRAS degraders
Open accessPublished version of a preprint
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS) protein are highly prevalent in cancer. However, small-molecule concepts that address oncogenic KRAS alleles remain elusive beyond replacing glycine at position 12 with cysteine (G12C), which is clinically drugged through covalent inhibitors. Guided by biophysical and structural studies of ternary complexes, we designed a heterobifunctional small molecule that potently degrades 13 out of 17 of the most prevalent oncogenic KRAS alleles. Compared with inhibition, KRAS degradation results in more profound and sustained pathway modulation across a broad range of KRAS mutant cell lines, killing cancer cells while sparing models without genetic KRAS aberrations. Pharmacological degradation of oncogenic KRAS was tolerated and led to tumor regression in vivo. Together, these findings unveil a new path toward addressing KRAS-driven cancers with small-molecule degraders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PROTAC (proteolysis-targeting chimera) technologies are designed to induce selective degradation of KRAS proteins through recruitment of E3 ubiquitin ligases and subsequent proteasomal destruction [61,62,63,64].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [62]
Citations
Cites
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination
Punjani, A., Rubinstein, J. L., Fleet, D. J., & Brubaker, M. A. (2017) · Nature Methods · doi:10.1038/nmeth.4169 · Cited by 11,626
UCSF ChimeraX: Structure visualization for researchers, educators, and developers
Pettersen, E. F., Goddard, T. D., Huang, C. C., Meng, E. C., Couch, G. S., Croll, T. I., Morris, J. H., & Ferrin, T. E. (2021) · Protein Science · doi:10.1002/pro.3943 · Cited by 9,514
Liebschner, D., Afonine, P. V., Baker, M. L., Bunkóczi, G., Chen, V. B., Croll, T. I., Hintze, B., Hung, L.-W., Jain, S., McCoy, A. J., et al. (2019) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798319011471 · Cited by 7,953
Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool
Chen, E. Y., Tan, C. M., Kou, Y., Duan, Q., Wang, Z., Meirelles, G. V., Clark, N. R., & Ma’ayan, A. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-128 · Cited by 7,814
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Data processing and analysis with the autoPROC toolbox
Vonrhein, C., Flensburg, C., Keller, P., Sharff, A., Smart, O., Paciorek, W., Womack, T., & Bricogne, G. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911007773 · Cited by 2,029
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Cited by
Items 101–199 of 199
Progress in targeting the untouchables: emerging approaches for hard-to-drug cancer targets
Coleman, N., Tan, H., & Rodon, J. A. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.01.012 · Cited by 4
Structural dynamics of the midnolin-proteasome during ubiquitin-independent substrate turnover
Zhu, C., Qin, L., Dai, Z., Zuo, P., Yang, A., Zhong, L., Lin, Z., & Liang, L. (2026) · Nature Communications · doi:10.1038/s41467-026-71002-0 · Cited by 4
Lu, X., Qin, J., Dong, S., Yuan, Y., Zhang, Z., Zhang, B., Chen, X., Gan, X., Liang, H., & Liu, F. (2026) · Biomarker Research · doi:10.1186/s40364-026-00937-9 · Cited by 3
“The main research on PROTAC targeting Pan-KRAS includes: Popow et al. reported the development of bifunctional PROTAC capable of targeting the remaining oncogenic KRAS mutations and found that ACBI3 could selectively degrade most oncogenic KRAS mutations [135].”
Su, G., Wang, Y., & Yao, L. (2026) · Pharmaceuticals · doi:10.3390/ph19070988 · Cited by 2
“…shorter timescale: the degradation of endogenous KRAS(G12C) by LC-2 [20] was followed within four years by a pan-KRAS degrader active against 13 of 17 clinically relevant mutants [34] and by the selective G12D degrader ASP3082, whose VHL ternary complex has been crystallographically resolved [35].”
Targeted protein degradation: bridging chemical biology and clinical translation
Zhang, Y., Fu, J.-W., Liu, Y., Wu, R. Y., Liang, Y., Zhang, W., Yuan, T., Zhu, H., He, Q.-J., & Yang, B. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01861-2 · Cited by 5
“This broad degradation pro fi le makes it particularly effective at overcoming EGFR-mediated feedback loops [60].”
Su, Z., Yin, S., & Wu, Y. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c06497 · Cited by 2
Emerging pharmacology of targeted protein degraders
Barghout, S. H., & Eldeeb, M. A. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103694 · Cited by 2
Covalent inhibitors of K-Ras G12S, G12R, and G12D
Zhang, Z., & Shokat, K. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00024-3 · Cited by 3
Jean-Francois, F. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00010-3 · Cited by 1
Computational approaches to aid PROTAC drug discovery
Chakraborti, S., & McAulay, K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00004-2 · Cited by 2
Rathod, D., Vats, M., Gawali, P., Otagho, O., Dholariya, B. M., & Patel, K. R. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2524312 · Cited by 2
An opportune time for targeted brain arteriovenous malformation therapy
Hale, A. T., Kalailingam, P., Kundishora, A. J., Reeves, B. C., Brastianos, P. K., Shih, H. A., Jain, R. K., Ning, M., Stapleton, C. J., Patel, A. B., et al. (2025) · Journal of neurosurgery · doi:10.3171/2025.4.jns25260 · Cited by 2
Novel paradigms in KRAS targeting: Unveiling strategies to combat drug resistance
Luo, X., Zhou, F., Tang, Y., Liu, X., Xiao, R., Gu, M., Bai, J., Jiang, D., Yang, G., You, L., et al. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003776 · Cited by 2
“[144] Examples include cancers driven by KRAS wt amplifications or NF1 tumor suppressor loss, as well as Type 1 neurofibromatosis or its associated malignancies.”
Development of highly potent and selective oncogenic KRASG12D PROTAC degraders
Mao, Y., Wei, P., Wei, T., Wang, Y., Qi, Z., Cai, X., Jia, C., Zhao, Z., Li, B., Qiao, M., et al. (2025) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2025.100296 · Cited by 4
Targeting RAS for Cancer Treatment: What a Long, Strange Trip It's Been
Cox, A. D., & Der, C. J. (2025) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-071024-082459 · Cited by 1
Sternicki, L. M., Crowe, C., Wieske, L. H. E., Ciulli, A., & Poulsen, S. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.6c01970 · Cited by 3
Self-citationThe evolving landscape of RAS-targeted therapies
Misale, S. (2025) · Nature Cancer · doi:10.1038/s43018-025-01077-z · Cited by 1
Du, J., Villemure, E., Johnson, M., Azumaya, C. M., Gaspar, C. J., Marsters, S. A., Lawrence, D. A., Foster, S. A., Rohou, A. L., Cheung, T. K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66382-8 · Cited by 2
“VHL associates via G6374 with the N-lobe of the IRE1-kinase domain in the forewings, with a total buried surface area (BSA) of ~300Å 2 — an interface that is comparable to known VHL:bromodo-main:PROTAC assemblies 50,51 (Supplementary Table 3).”
InfluentialIntrinsic resistance to RAS inhibitors is driven by dysregulation of KRAS degradation
Ivanišević, T., Ma, Y., Boxel, E. V., Magits, W., Lechat, B., Koçberber, Z., Willnow, P., Fendt, S., Velde, G. V., Sewduth, R. N., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67109-5 · Cited by 3
Furuhata, T., Yoshida, K., 凌嘉, 藤., Miyamoto, J., Moriyama, C., Masuda-Ozawa, T., Tsuchiya, H., Saeki, Y., & Okamoto, A. (2026) · Communications Chemistry · doi:10.1038/s42004-026-01895-x · Cited by 4
“…of all associated functions of the target proteins by irreversible degradation allows the targeting of proteins that were once regarded as undruggable targets 6 – 9 , includingmultifunctionalproteinswithscaffoldingcapabilities 10 – 12 ,pseudo-enzymes 13 , and nucleic acid-binding proteins 14 – 18 .”
PRMT3-Mediated Arginine Methylation Stabilizes PCSK9 to Promote Aortic Valve Calcification
Zhang, X., Hao, Y., Han, D., Jin, X., Shang, X., Zhang, L., Gan, Z., Ye, W., Wang, S., Li, X., et al. (2026) · Circulation · doi:10.1161/circulationaha.125.078830 · Cited by 4
Huang, Q., Mu, Q., Liu, N., Liu, G., & Liu, C. (2026) · Advanced Interventional Materials · doi:10.1016/j.advim.2026.100015 · Cited by 4
Won, H.-J., Baek, S. M., Lee, M. H., Park, J. H., Shin, J., Yang, Y., Jang, Y. H., Inn, K., & Kim, N. (2026) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202501208 · Cited by 3
Tanga, S., Das, P., Samoi, T. B., Hota, A., Karmakar, A., & Maji, B. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115874 · Cited by 1
KRAS and MYC synergistic inhibition: a powerful strategy targeting KRAS-mutant cancers
Yan, M., Liu, K., Xu, J., Liu, Y., Ji, L., & Zhang, S. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02659-w · Cited by 1
“This interaction leads to ubiquitination, subsequent degradation, and more substantial and enduring inhibition [149, 150].”
Targeted proteoform degradation for precision drug design, delivery, and therapy
Cui, C., Zhang, H., Wang, X., Li, N., & Zhan, X. (2026) · Drug Delivery · doi:10.1080/10717544.2026.2665871 · Cited by 2
“…KRAS protein: genomic variations such as G12D or G12V mutations generate KRAS proteoforms with constitutive GTPase activity, which constitutively activate the MAPK signaling pathway to drive tumor proliferation, whereas wild-type KRAS exhibits tightly regulated GTP/GDP cycling (Popow et al. 2024).”
Proteomics‐Driven Strategies for Proximity‐Inducing Drug Discovery
Fan, R., Ni, J., Zhou, T., Jiang, H. Q., Zhao, W., & Tan, M. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.3307512 · Cited by 1
Xiao, X.-Z., Wang, Y.-J., Pang, X.-F., & Zhang, A. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01866-x · Cited by 2
“This has led to the development of several degraders, including KRAS G12C PROTAC LC-2 [14], KRAS G12D PROTAC ASP3082 [15], and pan-KRAS PROTACs such as MCB-36 [10], ACBI3 [16], and ACBI4 [17].”
RAS signaling at the crossroads of radioresistance and tumor immunity
Quevrin, C., Mondini, M., Meziani, L., de Thoré, M. G., Liu, W., Lopes, E., Morel, D., Clémenson, C., Deutsch, É., & Lévy, A. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-015274 · Cited by 1
“94 Such deeper pathway suppression could influence DNA damage responses, redox homeostasis, and immune signaling, further reinforcing the rationale for integration with RT.”
Hu, L., Ahmari, N., Schaeper, A., Pundavela, J., Kim, M., Dombi, E., Wu, J., Brunmair, J., Petronczki, Ö. Y., & Ratner, N. (2026) · Science Advances · doi:10.1126/sciadv.aeg3475 · Cited by 2
“Those expected to target the WT RAS present in NF1 mutant cells include KRAS degrader molecules ( 59 , 60 ) and some RAS(ON) molecules, which preferentially inhibit RAS in the GTP-bound state ( 61 ).”
Stimulated protein degradation to promote mitochondrial function and neuronal survival
Chandrasekhar, S., McMinimy, R. A., Manford, A. G., Wehri, E., Gee, C. L., Miller, C., Bingol, B., Kuriyan, J., Schaletzky, J., & Rapé, M. (2026) · Science · doi:10.1126/science.aed2525 · Cited by 1
Substrate recognition by Cullin-RING ubiquitin ligase and chemical intervention
Xu, C., Fan, X., Gao, X., & Qi, W. (2024) · Scientia Sinica Chimica · doi:10.1360/ssc-2024-0242 · Cited by 1
The Potential of Pan-KRAS Inhibitors in the Treatment of KRAS-Mutant Leukemias
Boston, M., & Bondarenko, O. (2025) · The American Journal of Applied Sciences · doi:10.37547/tajas/volume07issue06-03 · Cited by 1
CircRNA-miRNA-mRNA interactome analysis to explore potential pathogenesis of ovarian cancer
Srivastava, R. (2025) · Next research. · doi:10.1016/j.nexres.2025.100508 · Cited by 2
Targeted KRAS G12V degradation elicits efficient and durable lung adenocarcinoma regression in vivoPreprint
Martín, A. J. M., García-Pérez, I. M., José, S. S., Rojo, P., Riego‐Mejías, C., Teodósio, C., Barbosa, B. M. G., Sánchez, C., Folch-I-Casanovas, I., Caballol, A. O., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.13.627539 · Cited by 1
Targeted Protein Degradation: From Basic Science to Therapeutic Applications
Zhu, R., Tang, X., & Zhang, H. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.5c00067 · Cited by 3
Kano, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135796
The emergence of pan-KRAS drugs
McConnell, D. B., & Kraut, N. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00019-x
From Mechanisms to Therapeutics: Tackling Resistance in EGFR, KRAS, and ALK in NSCLC
Liu, H. (2025) · Highlights in Science Engineering and Technology · doi:10.54097/0trsfx05 · Cited by 1
“Unlike inhibitors, KRAS degradation leads to deeper and more sustained pathway regulation, killing cancer cells without harming non-mutated models, offering a new therapeutic approach for KRAS-driven cancers [25].”
Uev1A counteracts oncogenic Ras stimuli in both polyploid and diploid cells
Zhang, Q., Wang, Y., Fu, X., Wang, Z., Zhang, Y., Yan, L., Wang, Y., Yang, M., Song, D., Zhang, R., et al. (2026) · eLife · doi:10.1101/2025.04.17.649440
Krasg12d Selective Vhl-Protac with Sparing Kraswt and Other Kras MutantsPreprint
Sim, T., Jeon, E., Kim, C., Ko, M., Kim, T. K., Bae, J., Oh, J. W., Kim, K. P., & Kim, H. S. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5254645
Uev1A counteracts oncogenic Ras stimuli in both polyploid and diploid cellsPreprint
Zhang, Q., Wang, Y., Fu, X., Wang, Z., Zhang, Y., Yan, L., Wang, Y., Yang, M., Song, D., Zhang, R., et al. (2025) · eLife · doi:10.7554/elife.107104.1
Uev1A counteracts oncogenic Ras stimuli in both polyploid and diploid cellsPreprint
Zhang, Q., Wang, Y., Fu, X., Wang, Z., Zhang, Y., Yan, L., Wang, Y., Yang, M., Song, D., Zhang, R., et al. (2025) · eLife · doi:10.7554/elife.107104
Zanders, E. D. (2025) · Springer eBooks · doi:10.1007/978-3-031-93949-5_6 · Cited by 1
Targeting KRAS in Cancer Therapy: Beyond Inhibitors
Chen, C., Peng, Z., & Zhang, L. (2025) · MedComm · doi:10.1002/mco2.70267
An ultrasonically sensitive small-molecule chimera for sono-controllable proteolysis
Zhang, B., Wang, S., Li, C., Zhou, S., Zhang, Y., Xu, G., & Li, J. (2025) · Chemical Communications · doi:10.1039/d5cc02435h
Gu, J., Guo, Y., Liu, R., Ge, D., Pan, Z., Chen, Z., Zhang, Y., Zhuma, K., Guo, Z., Jiao, M., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7223043/v1
Improved Maximum Matching for Constrained Structural Controllability of Directed Networks
Gao, X., Wang, P., & Lü, J. (2025) · IEEE Transactions on Network Science and Engineering · doi:10.1109/tnse.2025.3596883 · Cited by 1
“…such as phosphatases, transcription factors, and RAS family members, remain undruggable by traditional methods due to the absence of suitable drug-binding sites or limitations imposed by selective catalytic inhibitors and functional interactions with DNA or co-regulatory proteins [33], [34].”
Sugimori, M., Hirotani, A., Yamazaki, H., Oshi, M., Kawashima, K., Tsuchiya, H., Kanemaru, Y., Suzuki, Y., Onodera, S., Miwa, H., et al. (2025) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2025.100221
Yang, X., Zhu, J., & Wu, H. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003878
Verhoef, C. J. A., Crowe, C., Nakasone, M. A., Basté, A. D. L. C., Harzing, T., Span, N. A. S., Sathe, G. J., Iso, K., Ottmann, C., Brunsveld, L., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.17.688825
Self-citationPietra, F. (2025) · Medicinal Chemistry Research · doi:10.1007/s00044-025-03500-7
“Also degraders are being more and more used in recent times [7].”
Mohammed, O. S., Rasul, H. O., & Shwan, D. M. S. (2025) · Medical Oncology · doi:10.1007/s12032-025-03094-5
Ovarian Cancer Susceptibility and Chemosensitivity to KRAS Modulation
Psaras, A. M., McKay, S. J., Vilela, J. V., Sanchez, E. O., Cintrón, M. G., Elder, K. K., & Brooks, T. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031571
“…FDA-approved KRAS G12C inhibitors sotorasib (2021) [18] and adagrasib (2022) [19], investigational KRAS G12D inhibitor MRTX1133 [20], and pan-KRAS inhibitors BI-2865 (GDP-state) and RMC-6236 (GTP-state) [21,22]—have opened new therapeutic avenues to therapeutically target the KRAS pathway.”
A highly promising new avenue for targeting K-RAS: The small-molecule degrader XMU-MP-9
Jin, J. J. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.012
Uev1A counteracts oncogenic Ras stimuli in both polyploid and diploid cellsPreprint
Zhang, Q., Wang, Y., Fu, X., Wang, Z., Zhang, Y., Yan, L., Wang, Y., Yang, M., Song, D., Zhang, R., et al. (2026) · eLife · doi:10.7554/elife.107104.2
Crosstalk between protein lipidation and ubiquitination in tumor biology
Liao, J., Huang, Q., Yang, Z., Zou, M., Ren, J., Fang, R., Wen, J., Gao, Y., Peng, J., & Hao, L. (2026) · APOPTOSIS · doi:10.1007/s10495-026-02277-3
Frisch, A., Martin, E., Cannon, T. L., Wadlow, R. C., Raghavan, S., Sen, T., & Karim, N. A. (2026) · Current Oncology · doi:10.3390/curroncol33030148
“ACBI3 is another PROTAC degrader that showed promise in vivo with degradation of 13/17 main KRAS mutations with the goal of suppressing KRAS mutants altogether [61].”
Pinto-Fernández, A., Heride, C., Turnbull, A. P., Pedroso, D. C. S., Smith, V., Mullee, L., Krajewski, W. W., Bell, C., Varca, A. C., Charlton, T. M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.17.712179
Cancer biology and the principles of targeted cancer drug discovery
Davies, A., Jones, G., Krishnan, S., Krishnamoorthy, M., Maruggi, M., Kaneda, M., & Marjon, K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00035-2
Kwok, G. W., Lo, J., & Fung, T. H. W. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70353
“Popow and colleagues optimized a molecule that bifunctionally binds KRAS and the VHL-ubiquitin ligase and were successful in the degradation of 13/17 KRAS mutants [42].”
Innovative targeted therapies for mosaic RAS-related vascular malformations
Morin, G. (2024) · theses.fr (ABES) · doi:10.70675/88882e5fz1bf9z4dbezae13zba4200ee9598
Unlocking drug sensitivity in KRAS
MingCong, L. I., YueSong, Z. H. O. U., Qiao, T. D., QingLin, B. A. I., & Li, C. (2026) · Scientia Sinica Vitae · doi:10.1360/ssv-2025-0279
“例 如 , Popow 等人 [76] 基于 BI-2865 构建的 PROTAC 分子 (compound 4) 通过 VHL 连接子实现对多种 KRAS 突 变体的降解 , 在 17 种 KRAS 突变中对 13 种表现出高效 降解活性 , 为实现 “ 广谱 KRAS” 靶向治疗提供可能 , 由于其独特的作用方式 , 可能引发不同于传统抑制 剂的新型耐药机制 [76,77] .”
Expanding the Druggable Proteome with Tech Advances
Yesavage, T. (2026) · Genetic Engineering & Biotechnology News · doi:10.1177/1935472x261438928
Zhang, H., Yang, S., Wang, Y., Niu, M., & She, J. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2684700
“…superior to that of other clinical-stage agents 17 . the small-molecule acBi3 degrades KRas proteins harbouring 13 different mutations through the recruitment of e3 ubiquitin ligases 18 . siRNa-eFtX-G12V selectively silences mutant KRas G12V , with no effect on wild-type KRas or other isoforms 19 .”
Proteomics‐Driven Strategies for Proximity‐Inducing Drug Discovery
Fan, R., Ni, J., Zhou, T., Jiang, H. Q., Zhao, W., & Tan, M. (2026) · Angewandte Chemie · doi:10.1002/ange.3307512
Shen, J., Ma, Y., Wang, Y., Yang, M., Liang, T., & Guo, L. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118184 · Cited by 1
Targeting conventionally intractable cancer-driving proteins: What has been achieved recently?
Xie, Q., Xu, W., Wang, Y., & Ma, X. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119102
Ajay, N., Anilkumar, A. S., & Veerabathiran, R. (2026) · Seminars in Oncology · doi:10.1016/j.seminoncol.2026.152520
Daraxonrasib and Beyond: Pan‐ RAS Inhibition, Resistance, and Next‐Generation Strategies
Honda, R. P. (2026) · Cancer Science · doi:10.1111/cas.70497
“…early clinical development, including the G12D-selective agents PT0253 and ARV-806 and the pan-KRAS degraders ASP5834 and PT0511, all of which are being evaluated in the phase I portions of first- in-human studies (Clini calTr ials. gov: NCT06797336, NCT07023731, NCT07094204, and NCT07300150) [30].”
Development of Oncolytic Virus-Proteolysis-Targeting Chimera Conjugates for Tumor Immunotherapy
Gao, Z., Huang, H., Zhi, Y., Wu, H., Guo, Y., Dong, Y., Du, Y., Ji, Z., Yang, S., Wang, Y., et al. (2026) · ACS Nano · doi:10.1021/acsnano.5c21715
Ji, X. L., Du, Y., Zhang, Q., Zong, B., Du, K., He, X., Wu, G., Liang, C., 胡磬遥, Zhang, Y., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01832
Engineering Antibodies into Targeted Chimeras: From Recognition Modules to Programmable Degraders
Chen, K., & Hu, Q. (2026) · Advanced Science · doi:10.1002/advs.77142 · Cited by 2
“This logic has been highly successful for intracellular proteins, especially through small-molecule targeted protein degradation [ 7–9 ].”
Jin, S., Zhang, Z., Liang, F., Yang, Y., Lü, A., & Liang, C. (2026) · Biomarker Research · doi:10.1186/s40364-026-00981-5
“This pan-KRAS PROTAC remains at the pre-clinical stage but demonstrated robust anti-tumor efficacy across multiple KRAS-mutant cancer cell lines and in vivo murine tumor models [229].”
KRASG12V Degraders Provide a Potential Therapeutic Opportunity in Lung Adenocarcinoma
Borrego, S. G., & Misale, S. (2026) · Cancer Research · doi:10.1158/0008-5472.can-26-2186
Wang, C., Ghosh, P., Jin, S., Bai, L., Aguilar, A., McEachern, D., Wang, M., Li, Q., Wen, B., Sun, D., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01153
Jeon, E., Song, J., & Sim, T. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2719780
Yu, L., Ma, Y., Pang, Y., & Shen, X. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.6c02273
Elamin, K. M., Elbashir, S. M. I., & Adam, I. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177511
“ACBI3 provides a complementary proof of principle for von Hippel–Lindau protein (VHL)-mediated degradation across multiple oncogenic KRAS variants, including G12D, although it is more accurately classified as a pan-KRAS degrader than as a G12D-specific degrader [24].”
Lee, Y., Hwang, S., Shin, H. Y., Choi, K., Seo, S., Kim, H., Yang, J. S., Kim, Y. J., Kim, Y.-M., & Song, E. J. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01837-6 · Cited by 1
“However, PROTACs also face several limitations 84 .”
InfluentialWang, E., Yao, A., Sasaki, M., Tanaka, R., Hassanein, M., Fujiwara, Y., & Tokuhara, T. (2026) · Journal of Clinical Question · doi:10.69854/jcq.2026.0026
PADI-dependent mitochondrial adaptation drives resistance to KRAS inhibitors
Gani, M., Agostini, F., Secco, L., Pino, L. D., Picco, R., Licastro, D., Tolotto, V., D’Este, F., Choudhary, H., Ferino, A., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.118016
Zeng, S., Zhao, Y., Liu, Y., shen, Y., Zhu, Z., Chen, B., Li, X., Zhang, L., Zhang, J., Zhu, Y., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119362
Fitness criteria for PROTACs as chemical probes: principles and applications
Sturbaut, M., & Ciulli, A. (2026) · Essays in Biochemistry · doi:10.1042/ebc20260006 · Cited by 1
Self-citationChan, S. C., Bayle, S., Lamptey, M., Lee-Sam, A., Sun, L., Grassie, D., Kakumanu, R., Sansil, S., Schönbrunn, E., Duckett, D. R., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01340
Advances in KRASG12D-targeted therapy: from small-molecule inhibitors to PROTACs and molecular glues
Hao, S., Niu, T., Wu, X., Mu, C., Wang, M., Liu, H., & 路海滨 (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110633
Fatahichegeni, M., Ansarian, M. A., Wang, Y., Zhang, T., Liu, R., Ren, J., & Wang, X. (2026) · Leukemia Research · doi:10.1016/j.leukres.2026.108336
Proteome-guided drug discovery maps and mitigates therapeutic degrader toxicity
Basu, S., Yu, J., Bosak, J., Bagal, S. K., Crafter, C., Fallan, C., Lemke, O., Freiwald, A., White, M. E. H., Vernardis, S. I., et al. (2026) · Nature Chemical Biology · doi:10.1038/s41589-026-02347-2
Jaki, M., Dari, L., Köll-Weber, M., Hermann, A., Wenzel, C., Pollak, A., Lembeck, J., Kaul, L., Balzer, B. N., Wittmann, M., et al. (2026) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2026.107686
NAT10 exacerbates aortic valve calcification via PCSK9 mRNA ac4C acetylation
Liu, Y., Li, X., Zhou, T., Xie, J., Jiang, H., Zheng, B., Peng, J., Li, L., Han, D., & Wang, Y. (2026) · iScience · doi:10.1016/j.isci.2026.117812
Wang, T., Ji, C., & Zhao, T. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1967704
“The VHL-recruiting degrader ACBI3, reported in 2024, efficiently degraded 13 of 17 common oncogenic KRAS alleles.”
Influential王海英, Chen, H., Li, S., & Zhao, J. (2026) · Cancer Innovation · doi:10.1002/cai2.70082
Deprez-Poulain, R. F., Hirsch, A. K. H., Heitman, L. H., Missbach, M., Tran, M. T., Ciulli, A., Riniker, S., & Poljak, T. (2026) · ChemMedChem · doi:10.1002/cmdc.70535
“…developed in the Ciulli laboratory, including the LRRK2 degrader XL01126 [44], the SMARCA2 PROTAC degraders ACBI1 and ACBI2 [45, 46], and the pan‐KRAS degraders ACBI3 and ACBI4, the latter engaging and degrading also mutants locked in the active, GTP‐loaded state of KRAS, such as G12R [47, 48].”
Self-citationZheng, H., Liu, Z., Nie, S., Sun, J., Li, Z., Zhang, S., Zhang, S., Ma, S., Wang, X., & Qin, C. (2026) · Marine Life Science & Technology · doi:10.1007/s42995-026-00424-y
A Pan-KRAS-Targeted PET Probe for Noninvasive Quantitative Imaging of KRAS Expression
Guo, Q., Wang, D., Du, J., 刘金剑, Yang, L., & Liu, J. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6c01137
Peng, Y., & Li, M. (2026) · Digital Medical Engineering · doi:10.1021/dme.6c00011
BindingDB (2025) · UC San Diego · doi:10.7270/q23b64qb
Uncovering KRAS -mutant allele-specific biology and vulnerabilities in non-small cell lung cancer
d’Arienzo, P. D., McDaid, W. J., Tinsley, K. L., Chen, T., Gasson, E. J., Lindsay, C. R., & Malliri, A. (2026) · Biochemical Journal · doi:10.1042/bcj20250138
Tang, J., Cheng, Z., Xie, T., Zhuang, Y., Hu, H., Li, C., Wang, H., Feng, C., & Tu, C. (2026) · Biomarker Research · doi:10.1186/s40364-026-01032-9
Metadata
- Authors
- Popow, J., Farnaby, W., Gollner, A., Kofink, C., Fischer, G., Wurm, M., Zollman, D., Wijaya, A., Mischerikow, N., Hasenoehrl, C., Prokofeva, P., Arnhof, H., Arce-Solano, S., Bell, S., Boeck, G., Diers, E., Frost, A. B., Goodwin-Tindall, J., Karolyi-Oezguer, J., Khan, S., Klawatsch, T., Koegl, M., Kousek, R., Kratochvil, B., Kropatsch, K., Lauber, A. A., McLennan, R., Olt, S., Peter, D., Petermann, O., Roessler, V., Stolt-Bergner, P., Strack, P., Strauss, E., Trainor, N., Vetma, V., Whitworth, C., Zhong, S., Quant, J., Weinstabl, H., Kuster, B., Ettmayer, P., & Ciulli, A.
- Affiliations
- Boehringer Ingelheim (Austria) (AT)
- University of Dundee (GB)
- Technical University of Munich (DE)
- Boehringer Ingelheim (United States) (US)
- Division of Biological Chemistry and Drug Discovery, School of Life Sciences, James Black Centre, University of Dundee, Dundee DD1 5EH, UK.
- Boehringer Ingelheim RCV GmbH & Co KG, 1221 Vienna, Austria.
- Proteomics and Bioanalytics, School of Life Sciences, Technical University of Munich, 85354 Freising, Germany.
- Corresponding author
- Ciulli, Alessio
- ORCID
- Popow, Johannes
- Farnaby, William
- Gollner, Andreas
- Kofink, Christiane
- Fischer, Gerhard
- Wurm, Melanie
- Zollman, David
- Wijaya, Andre
- Prokofeva, Polina
- Arce-Solano, Silvia
- Bell, Sammy
- Boeck, Georg
- Diers, Emelyne
- Frost, Aileen B.
- Klawatsch, Theresa
- Koegl, Manfred
- Lauber, Arnel A.
- McLennan, Ross
- Peter, Daniel
- Stolt-Bergner, Peggy
- Trainor, Nicole
- Vetma, Vesna
- Whitworth, Claire
- Zhong, Siying
- Quant, Jens
- Weinstabl, Harald
- Kuster, Bernhard
- Ettmayer, Peter
- Ciulli, Alessio
- Venue
- Science
- Published
- 2024-09-20
- Volume
- 385
- Issue
- 6715
- Pages
- 1338-1347
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W4402625837
- Semantic Scholar
- ed61350af26b096749adcb45351f0e69feb359f3
- Cited by
- 198
- References
- 50
- Citations by year
- 2026: 78 · 2025: 94 · 2024: 26
- FWCI
- 26.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Science (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion, cc-by)
- DORA PSI (Paul Scherrer Institute) (submittedVersion)
- Funders
- University of Dundee
- Wellcome Trust (100476, 094090/Z/10/Z, 094090, 097945/C/11/Z, 097945, 100476/Z/12/Z)
- Diamond Light Source (MX14980)
- Medical Research Council
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- KRAS, oncogenic KRAS mutations, small-molecule degraders, heterobifunctional molecules, protein degradation, KRAS G12C, covalent inhibitors, ternary complex, KRAS-driven cancers, tumor regression
- MeSH terms
- Proteolysis Targeting Chimera, Alleles, Animals, Antineoplastic Agents, Humans, Mutation, Neoplasms, Proto-Oncogene Proteins p21(ras), Cell Line, Tumor, Mice, Small Molecule Libraries, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.